Current Report Filing (8-k)
October 04 2013 - 4:08PM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
FORM 8-K
|
|
CURRENT REPORT
|
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|
Date of Report (Date of earliest event reported) September 30, 2013
|
|
Tanke Biosciences Corporation
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
|
000-53529
|
|
26-3853855
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
|
Room 2801, East Tower of Hui Hao Building, No. 519 Machang Road, Pearl River New City,
Guangzhou, People’s Republic of China
|
|
510627
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Registrant’s telephone number, including area code +86-20-38859025
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 30, 2013, Gilbert Lee, Chief Financial Officer of Tanke Biosciences Corporation (“we,” “us” or the “Registrant”), submitted his written resignation to the Board of Directors of the Registrant, effective immediately. Mr. Lee’s decision to resign is not a result of any disagreement with us relating to our operations, policies or practices.
The Registrant is seeking qualified candidate to replace Mr. Lee, and in the interim other officers of the Registrant may fulfill Mr. Lee’s functions on an interim basis.
|
Item 9.01
|
Financial Statements and Exhibits
|
| |
|
| |
Exhibit No.
|
|
Exhibit
|
| |
|
|
|
| |
99.1
|
|
Resignation Letter of Gilbert Lee, dated September 30, 2013.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: October 4, 2013
|
TANKE BIOSCIENCES CORPORATION
|
| |
|
| |
By:
|
/s/ Guixiong Qiu
|
| |
|
Name:
|
Guixiong Qiu
|
| |
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Exhibit
|
| |
|
|
|
99.1
|
|
Resignation Letter of Gilbert Lee, dated September 30, 2013.
|
Tanke Biosciences (PK) (USOTC:TNBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Tanke Biosciences (PK) (USOTC:TNBI)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about Tanke Biosciences Corporation (PK) (OTCMarkets): 0 recent articles
More Tanke Biosciences Corp News Articles
